Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Salvages Deal With Guidant: $4 Bil. Shaved Off Purchase Price

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's renegotiated deal to acquire Guidant for $21.5 bil. will make medical devices the firm's largest business segment once the merger closes
Advertisement

Related Content

Guidant Shareholders To Vote On J&J Offer; Boston Scientific Still Interested
Guidant Shareholders To Vote On J&J Offer; Boston Scientific Still Interested
Boston Scientific Offers $25 Bil. To Nab Guidant From J&J
Boston Scientific Offers $25 Bil. To Nab Guidant From J&J
Dollens, In Final Speech As CEO, Says Industry Should Publicize Device Risks
Dollens, In Final Speech As CEO, Says Industry Should Publicize Device Risks
J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes
J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes
Guidant Files Lawsuit To Force J&J To Complete Acquisition
Cypher Shines At Taxus’ Expense: J&J Captures 46% Of U.S. Market
Advertisement
UsernamePublicRestriction

Register

MT022920

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel